Aller à la navigation principale
Skip notifications
À compter du 1er décembre 2023, l’accès à POEMs et à Essential Evidence Plus ne fera plus partie des avantages offerts aux membres de l’AMC.
Search
Medical cannabis use not supported by a wealth of research
Question clinique
What is the evidence supporting the use of medical cannabis?
L’Essentiel
Cannabis-related products are not well studied and when they have been they have come up short in the treatment of most mental disorders, including Tourette's, depression, attention deficit hyperactivity disorder, post-traumatic stress disorder, psychosis, and anxiety. Pharmaceutical grade tetrahydrocannabinol (THC) provides a small benefit in anxiety symptoms in patients with chronic non-cancer pain and multiple sclerosis. Though not included in this review, the UK National Institute for Health and Care Excellence recommends cannabidiol for seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, as well as to controls spasms and spasticity associated with multiple sclerosis [LINK TO: https://www.bmj.com/content/367/bmj.l6453] 2a-
Référence
Plan de l'etude: Meta-analysis (other)
Financement: Government
Cadre: Various (meta-analysis)
Sommaire
This meta-analysis identified 83 randomized and nonrandomized studies that investigated the effectiveness of cannabis or cannabinoids (the active ingredients in cannabis) in the treatment of various mental problems by searching 4 databases as well as unpublished and ongoing studies. Two authors independently selected articles for inclusion, abstracted the data, and graded study quality; they also evaluated relevance and directness of results along with risk of bias. Overall, the quality of evidence is low, which is no surprise since there is no mega-pharma company with patent exclusivity requiring governments and other groups to develop the database. Despite many studies, cannabinoid (THC or cannabidiol) treatment has not been shown to be effective for depression, psychosis, or anxiety. Cannabinoids have been studied, without evidence of benefit, in patients with Tourette syndrome, adult attention-deficit/hyperactivity disorder, and posttraumatic stress disorder. Pharmaceutical-grade THC (7 studies, 252 patients) improves anxiety symptoms in patients with chronic noncancer pain and multiple sclerosis, though the effect size is small (standardized mean difference = .25).
Reviewer
Allen F. Shaughnessy, PharmD, MMedEd
Professor of Family Medicine
Tufts University
Boston, MA
Commentaires
Despite the low quality the…
Despite the low quality the findings are in line with my clinical experience.